83 FR 47633 - National Institute on Drug Abuse; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 83, Issue 183 (September 20, 2018)

Page Range		47633-47634
FR Document		2018-20423

Federal Register, Volume 83 Issue 183 (Thursday, September 20, 2018)

[Federal Register Volume 83, Number 183 (Thursday, September 20, 2018)]
[Notices]
[Pages 47633-47634]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2018-20423]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meetings

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meetings.
    The meetings will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Exploiting Omics Assays to Investigate Molecular 
Regulation of Persistent HIV in

[[Page 47634]]

Individuals with Substance Use Disorder (R61/R33 Clinical Trial 
Optional).
    Date: October 3, 2018.
    Time: 12:00 p.m. to 4:30 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4228, MSC 9550, Bethesda, MD 20892, 
301-827-5842, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Exploring Epigenomic or Non-Coding RNA Regulation in 
the Development, Maintenance, or Treatment of Chronic Pain (R61/R33 
Clinical Trial Optional).
    Date: October 12, 2018.
    Time: 12:00 p.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Ipolia R. Ramadan, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, Division of 
Extramural Research, National Institute on Drug Abuse, NIH, DHHS, 
6001 Executive Boulevard, Room 4228, MSC 9550, Bethesda, MD 20892, 
301-827-5842, [email protected].

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Coordinating Center to Support NIDA Rural Opioid HIV 
and Comorbidity Initiative (U24--Clinical Trial Not Allowed).
    Date: October 17, 2018.
    Time: 2:00 p.m. to 4:30 p.m.
    Agenda: To review and evaluate cooperative agreement 
applications.
    Place: National Institutes of Health, Neuroscience Center, 6001 
Executive Boulevard, Rockville, MD 20852 (Telephone Conference 
Call).
    Contact Person: Hiromi Ono, Ph.D., Scientific Review Officer, 
Office of Extramural Policy and Review, National Institute on Drug 
Abuse, National Institutes of Health, DHHS, 6001 Executive 
Boulevard, Room 4238, MSC 9550, Bethesda, MD 20892, 301-827-5820, 
[email protected].

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: September 14, 2018.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2018-20423 Filed 9-19-18; 8:45 am]
 BILLING CODE 4140-01-P

Federal Register / Vol. 83, No. 183 / Thursday, September 20, 2018 / Notices 47633

Contact Person: Liliana Norma Berti- and personal information concerning provisions set forth in sections
Mattera, Ph.D., Scientific Review Officer, individuals associated with the contract 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Center for Scientific Review, National proposals, the disclosure of which as amended. The grant applications and
Institutes of Health, 6701 Rockledge Drive,
would constitute a clearly unwarranted the discussions could disclose
Room 4215, Bethesda, MD 20892,
liliana.berti-mattera@nih.gov. invasion of personal privacy. confidential trade secrets or commercial
Name of Committee: Healthcare Delivery Name of Committee: National Institute on property such as patentable material,
and Methodologies Integrated Review Group; Drug Abuse Special Emphasis Panel; State-of- and personal information concerning
Community-Level Health Promotion Study the-Art Functional MRI Approaches individuals associated with the grant
Section. Combined with MVPA (9916). applications, the disclosure of which
Date: October 15–16, 2018. Date: October 4, 2018. would constitute a clearly unwarranted
Time: 8:00 a.m. to 6:00 p.m. Time: 10:00 a.m. to 12:00 p.m. invasion of personal privacy.
Agenda: To review and evaluate grant Agenda: To review and evaluate contract
applications. proposals. Name of Committee: Microbiology,
Place: Westin Georgetown, 2350 M Street, Place: National Institutes of Health, Infectious Diseases and AIDS Initial Review
Neuroscience Center, 6001 Executive Group; Microbiology and Infectious Diseases
NW, Washington, DC 20037.
Boulevard, Rockville, MD 20852 (Telephone Research Committee.
Contact Person: Ping Wu, Ph.D., Scientific
Date: October 18–19, 2018.
Review Officer, Center for Scientific Review, Conference Call).
Time: 8:00 a.m. to 5:30 p.m.
National Institutes of Health, 6701 Rockledge Contact Person: Lyle Furr, Scientific
Agenda: To review and evaluate grant
Drive, Room 3166, Bethesda, MD 20892, 301– Review Officer, Office of Extramural Affairs,
applications.
451–8428 wup4@csr.nih.gov. National Institute on Drug Abuse, NIH,
Place: National Institutes of Health, 5601
Name of Committee: Center for Scientific DHHS, Room 4227, MSC 9550, 6001 Fishers Lane, Rockville, MD 20892
Review Special Emphasis Panel; RFA–GM– Executive Boulevard, Bethesda, MD 20892– (Telephone Conference Call).
18–002: Training Modules to Enhance the 9550, (301) 827–5702, lf33c.nih.gov. Contact Person: Amir E. Zeituni, Ph.D.,
Rigor and Reproducibility of Biomedical Name of Committee: National Institute on Scientific Review Program, Division of
Research (R25). Drug Abuse Special Emphasis Panel; Extramural Activities, SRP, RM 3G51
Date: October 16, 2018. Assessment of Potential Substance Abuse National Institutes of Health, NIAID, 5601
Time: 10:00 a.m. to 3:00 p.m. Treatment Medications in Nonhuman Fishers Lane, MSC 9823, Rockville, MD
Agenda: To review and evaluate grant Primate Models (8946). 20852–9823, 301–496–2550, amir.zeituni@
applications. Date: October 18, 2018. nih.gov.
Place: National Institutes of Health, 6701 Time: 10:00 a.m. to 12:00 p.m. (Catalogue of Federal Domestic Assistance
Rockledge Drive, Bethesda, MD 20892 Agenda: To review and evaluate contract Program Nos. 93.855, Allergy, Immunology,
(Virtual Meeting). proposals. and Transplantation Research; 93.856,
Contact Person: Vonda K. Smith, Ph.D., Place: National Institutes of Health, Microbiology and Infectious Diseases
Scientific Review Officer, Center for Neuroscience Center, 6001 Executive Research, National Institutes of Health, HHS)
Scientific Review, National Institutes of Boulevard, Rockville, MD 20852 (Telephone
Health, 6701 Rockledge Drive, Room 6188, Conference Call). Dated: September 14, 2018.
MSC 7892, Bethesda, MD 20892, 301–435– Contact Person: Lyle Furr, Scientific Natasha M. Copeland,
1789, smithvo@csr.nih.gov. Review Officer, Office of Extramural Affairs, Program Analyst, Office of Federal Advisory
(Catalogue of Federal Domestic Assistance National Institute on Drug Abuse, NIH, Committee Policy.
Program Nos. 93.306, Comparative Medicine; DHHS, Room 4227, MSC 9550, 6001 [FR Doc. 2018–20422 Filed 9–19–18; 8:45 am]
93.333, Clinical Research, 93.306, 93.333, Executive Boulevard, Bethesda, MD 20892– BILLING CODE 4140–01–P
93.337, 93.393–93.396, 93.837–93.844, 9550, (301) 827–5702, f33c.nih.gov.
93.846–93.878, 93.892, 93.893, National (Catalogue of Federal Domestic Assistance
Institutes of Health, HHS) Program No.: 93.279, Drug Abuse and DEPARTMENT OF HEALTH AND
Dated: September 14, 2018. Addiction Research Programs, National
HUMAN SERVICES
Institutes of Health, HHS)
Melanie J. Pantoja,
Program Analyst, Office of Federal Advisory Dated: September 14, 2018. National Institutes of Health
Committee Policy. Natasha M. Copeland,
[FR Doc. 2018–20414 Filed 9–19–18; 8:45 am] Program Analyst, Office of Federal Advisory National Institute on Drug Abuse;
Committee Policy. Notice of Closed Meetings
BILLING CODE 4140–01–P
[FR Doc. 2018–20417 Filed 9–19–18; 8:45 am] Pursuant to section 10(d) of the
BILLING CODE 4140–01–P Federal Advisory Committee Act, as
DEPARTMENT OF HEALTH AND amended, notice is hereby given of the
HUMAN SERVICES following meetings.
DEPARTMENT OF HEALTH AND The meetings will be closed to the
National Institutes of Health HUMAN SERVICES public in accordance with the
provisions set forth in sections
National Institute on Drug Abuse; National Institutes of Health 552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
Notice of Closed Meetings
as amended. The grant applications and
National Institute of Allergy and
Pursuant to section 10(d) of the the discussions could disclose
Infectious Diseases Notice of Closed
Federal Advisory Committee Act, as confidential trade secrets or commercial
Meeting
amended, notice is hereby given of the property such as patentable material,
following meetings. Pursuant to section 10(d) of the and personal information concerning
The meetings will be closed to the Federal Advisory Committee Act, as individuals associated with the grant
amozie on DSK3GDR082PROD with NOTICES1

public in accordance with the amended, notice is hereby given of a applications, the disclosure of which
provisions set forth in sections meeting Microbiology, Infectious would constitute a clearly unwarranted
552b(c)(4) and 552b(c)(6), Title 5 U.S.C., Diseases and AIDS Initial Review Group invasion of personal privacy.
as amended. The contract proposals and Microbiology and Infectious Diseases Name of Committee: National Institute on
the discussions could disclose Research Committee. Drug Abuse Special Emphasis Panel;
confidential trade secrets or commercial The meeting will be closed to the Exploiting Omics Assays to Investigate
property such as patentable material, public in accordance with the Molecular Regulation of Persistent HIV in

VerDate Sep<11>2014 18:01 Sep 19, 2018 Jkt 244001 PO 00000 Frm 00034 Fmt 4703 Sfmt 4703 E:\FR\FM\20SEN1.SGM 20SEN1

47634 Federal Register / Vol. 83, No. 183 / Thursday, September 20, 2018 / Notices

Individuals with Substance Use Disorder DEPARTMENT OF HEALTH AND Addressing Harassment and
(R61/R33 Clinical Trial Optional). HUMAN SERVICES Inappropriate Conduct and a new Policy
Date: October 3, 2018. Statement addressing Personal
Time: 12:00 p.m. to 4:30 p.m. National Institutes of Health Relationships in the Workplace. These
Agenda: To review and evaluate grant policies apply to federal employees,
applications. National Institute on Aging; Notice of contractors, trainees, and fellows who
Place: National Institutes of Health, Closed Meeting perform work for the NIH. The NIH
Neuroscience Center, 6001 Executive expects that organizations receiving NIH
Boulevard, Rockville, MD 20852 (Telephone Pursuant to section 10(d) of the
Federal Advisory Committee Act, as funds have in place similarly rigorous
Conference Call).
amended, notice is hereby given of the policies and related procedures for their
Contact Person: Ipolia R. Ramadan, Ph.D.,
following meeting. employees, contractors, trainees, and
Scientific Review Officer, Office of
Extramural Policy and Review, Division of The meeting will be closed to the fellows who engage in agency-funded
Extramural Research, National Institute on public in accordance with the activities.
Drug Abuse, NIH, DHHS, 6001 Executive provisions set forth in sections FOR FURTHER INFORMATION CONTACT: For
Boulevard, Room 4228, MSC 9550, Bethesda, 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., further information about these new
MD 20892, 301–827–5842, ramadanir@ as amended. The grant applications and policies, contact Jessica Hawkins, Office
mail.nih.gov. the discussions could disclose of Human Resources, National Institutes
Name of Committee: National Institute on confidential trade secrets or commercial of Health, Building 31, Room 1/B37,
Drug Abuse Special Emphasis Panel; property such as patentable material, Bethesda, Maryland 20892, telephone
Exploring Epigenomic or Non-Coding RNA and personal information concerning 301–402–8006 (not a toll-free number),
Regulation in the Development, individuals associated with the grant hawkinj@od.nih.gov.
Maintenance, or Treatment of Chronic Pain applications, the disclosure of which SUPPLEMENTARY INFORMATION: Policy
(R61/R33 Clinical Trial Optional). would constitute a clearly unwarranted Manual 1311—Preventing and
Date: October 12, 2018. invasion of personal privacy. Addressing Harassment and
Time: 12:00 p.m. to 4:00 p.m.
Name of Committee: National Institute on Inappropriate Conduct states that the
Agenda: To review and evaluate grant
applications.
Aging Special Emphasis Panel; Institutional NIH will not tolerate inappropriate
Training Grants. conduct or harassment, including sexual
Place: National Institutes of Health,
Date: October 17, 2018. harassment. Timely and appropriate
Neuroscience Center, 6001 Executive Time: 9:00 a.m. to 1:00 p.m.
Boulevard, Rockville, MD 20852 (Telephone action will be taken against any
Agenda: To review and evaluate grant
Conference Call). individual found to be in violation of
applications.
Contact Person: Ipolia R. Ramadan, Ph.D., Place: Hyatt Regency Bethesda, One the policy outlined in the Manual
Scientific Review Officer, Office of Bethesda Metro Center, 7400 Wisconsin Chapter. Through enforcement of this
Extramural Policy and Review, Division of Avenue, Bethesda, MD 20814. policy, the NIH seeks to prevent,
Extramural Research, National Institute on Contact Person: Kimberly Firth, Ph.D., correct, and eliminate unacceptable
Drug Abuse, NIH, DHHS, 6001 Executive National Institutes of Health, National behavior that is inconsistent with the
Boulevard, Room 4228, MSC 9550, Bethesda, Institute on Aging, Gateway Building, 7201 values and culture of respect and
MD 20892, 301–827–5842, ramadanir@ Wisconsin Avenue, Suite 2C212, Bethesda, inclusion. Further, the policy is
mail.nih.gov. MD 20892, 301–402–7702, firthkm@ intended to increase the transparency
mail.nih.gov.
Name of Committee: National Institute on and consistency in how allegations of
Drug Abuse Special Emphasis Panel; (Catalogue of Federal Domestic Assistance harassment are reviewed and resolved.
Coordinating Center to Support NIDA Rural Program Nos. 93.866, Aging Research,
NIH leadership has designated the
Opioid HIV and Comorbidity Initiative National Institutes of Health, HHS)
Office of Human Resources’ Civil
(U24—Clinical Trial Not Allowed). Dated: September 14, 2018. Program as the entity charged with
Date: October 17, 2018. Melanie J. Pantoja, receiving allegations of harassment and
Time: 2:00 p.m. to 4:30 p.m. Program Analyst, Office of Federal Advisory overseeing relevant administrative
Agenda: To review and evaluate Committee Policy. inquiries.
cooperative agreement applications. The NIH Policy Statement on Personal
[FR Doc. 2018–20420 Filed 9–19–18; 8:45 am]
Place: National Institutes of Health, Relationships in the Workplace states
BILLING CODE 4140–01–P
Neuroscience Center, 6001 Executive
that personal relationships (including
Boulevard, Rockville, MD 20852 (Telephone
romantic and/or sexual) between
Conference Call).
Contact Person: Hiromi Ono, Ph.D.,
DEPARTMENT OF HEALTH AND individuals in inherently unequal
Scientific Review Officer, Office of HUMAN SERVICES positions, where one party has real or
Extramural Policy and Review, National perceived authority over the other in
Institute on Drug Abuse, National Institutes
National Institutes of Health their professional roles, may be
of Health, DHHS, 6001 Executive Boulevard, inappropriate in the workplace and are
Notice of New NIH Policy Manual strongly discouraged. If such a
Room 4238, MSC 9550, Bethesda, MD 20892,
1311—Preventing and Addressing relationship exists or develops, it must
301–827–5820, hiromi.ono@nih.gov.
Harassment and Inappropriate be disclosed. Upon such notification,
(Catalogue of Federal Domestic Assistance Conduct and New Policy Statement on
Program Nos.: 93.279, Drug Abuse and the responsible agency official must
Inappropriate Relationships in the insure that the NIH Institute/Center
Addiction Research Programs, National
Workplace manages, decreases, or eliminates
Institutes of Health, HHS)
amozie on DSK3GDR082PROD with NOTICES1

AGENCY: National Institutes of Health, potential risk as a result of the
Dated: September 14, 2018.
HHS. relationship.
Natasha M. Copeland, This applies to all individuals in the
ACTION: Notice.
Program Analyst, Office of Federal Advisory NIH community, including employees,
Committee Policy. SUMMARY: The National Institutes of contractors, students, trainees, and
[FR Doc. 2018–20423 Filed 9–19–18; 8:45 am] Health (NIH) announces Policy Manual fellows and includes anyone who holds
BILLING CODE 4140–01–P Chapter: 1311—Preventing and a position of authority or perceived

VerDate Sep<11>2014 18:01 Sep 19, 2018 Jkt 244001 PO 00000 Frm 00035 Fmt 4703 Sfmt 4703 E:\FR\FM\20SEN1.SGM 20SEN1

Document Created: 2018-09-20 02:08:43
Document Modified: 2018-09-20 02:08:43

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		October 3, 2018.
FR Citation		83 FR 47633

83 FR 47633 - National Institute on Drug Abuse; Notice of Closed Meetings

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 83, Issue 183 (September 20, 2018)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health